Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) has granted marketing authorization for TIVDAK® (tisotumab vedotin), an antibody-drug conjugate (ADC), as monotherapy ...

Genmab has received approval from the Japan's Ministry of Health, Labour and Welfare for Tivdak (tisotumab vedotin) to treat ...

Genmab has announced that the European Commission (EC) has approved Tivdak (tisotumab vedotin) to treat recurrent or ...

TIVDAK® is the first and only antibody-drug conjugate (ADC) approved to treat recurrent or metastatic cervical cancer with disease progression on or after systemic therapy In the global Phase 3 ...

Data from the innovaTV 204 (NCT03438396) pivotal Phase 2 single-arm clinical trial evaluating TIVDAK as monotherapy in patients with previously treated recurrent or metastatic cervical cancer was ...

Genmab (GMAB) announced that the European Commission has granted marketing authorization for TIVDAK, an antibody-drug conjugate, as monotherapy ...

Japan approves Tivdak, the first ADC for cervical cancer, after Phase 3 trial shows a 30% reduction in death risk vs. chemotherapy. The trial of 502 patients showed Tivdak improved median overall ...